Login to Your Account

Genzyme, Bayer Ink $2.9B Deal for Campath, Fludara, Leukine

By Trista Morrison

Wednesday, April 1, 2009
Genzyme Corp. bolstered its oncology portfolio through a potential $2.9 billion deal with partner Bayer AG that gives Genzyme rights to the marketed cancer drugs Campath (alemtuzumab), Fludara (fludarabine) and Leukine (sargramostim) - as well as control of the Phase III alemtuzumab program in multiple sclerosis. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription